- SEK84.45m
- SEK73.87m
Brief: Alzinova Q1 Loss After Financial Items SEK 6 Mln
Brief: Alzinova Initiates Collaboration With Amsterdam UMC
Brief: Alzinova Q4 Loss After Financial Items At SEK 5.9 Mln
Brief: Rights Issue Expected To Yield SEK 40.1 Mln In Proceeds for Alzinova
Brief: Alzinova Raises Proceeds Of About SEK 50 Mln From Rights Issue
Brief: Alzinova Enters MoU For Commercial Partnership In Saudi Arabia
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 6.96 Mln
Brief: Alzinova Enters Into SEK 11 Mln Loan Arrangement
Brief: Alzinova Gets Fast Track Designation from US FDA
Brief: Alzinova Gets FDA IND Approval For Phase II Study Of Alz-101 In Alzheimer's Disease
Brief: Alzinova Q2 Loss After Financial Items At SEK 7.7 Mln
Brief: Alzinova Submits IND Application To FDA For Phase II Study
Brief: Alzinova Provides Future Sales Forecast For ALZ-101
Brief: Alzinova Announces Results On Protective Antibodies in Alzheimer
Brief: Alzinova Q1 Loss After Financial Items Widens To SEK 5.7 Mln
Brief: Alzinova Rights Issue Subscribed To 85%
Brief: Alzinova Gets Letters Of Intent Ongoing Rights Issue
Brief: Alzinova Resolves On Rights Issue Of Shares Of About SEK 35.7 Mln
Brief: Final Data Confirm Positive Phase 1b Results With Alzinova's ALZ-101 Against Alzheimer's Disease